- Home
- OMAB vs NUVL Comparison
OMAB vs NUVL Comparison
Compare OMAB & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMAB
- NUVL
- Stock Information
- Founded
- OMAB 1998
- NUVL 2017
- Country
- OMAB Mexico
- NUVL United States
- Employees
- OMAB N/A
- NUVL N/A
- Industry
- OMAB Aerospace
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OMAB Consumer Discretionary
- NUVL Health Care
- Exchange
- OMAB Nasdaq
- NUVL Nasdaq
- Market Cap
- OMAB 4.8B
- NUVL 5.6B
- IPO Year
- OMAB 2006
- NUVL 2021
- Fundamental
- Price
- OMAB $100.43
- NUVL $75.00
- Analyst Decision
- OMAB Buy
- NUVL Strong Buy
- Analyst Count
- OMAB 4
- NUVL 8
- Target Price
- OMAB $102.50
- NUVL $115.50
- AVG Volume (30 Days)
- OMAB 59.1K
- NUVL 452.9K
- Earning Date
- OMAB 07-25-2025
- NUVL 08-07-2025
- Dividend Yield
- OMAB 4.53%
- NUVL N/A
- EPS Growth
- OMAB 2.49
- NUVL N/A
- EPS
- OMAB 0.65
- NUVL N/A
- Revenue
- OMAB $728,352,552.00
- NUVL N/A
- Revenue This Year
- OMAB $6.46
- NUVL N/A
- Revenue Next Year
- OMAB $12.84
- NUVL N/A
- P/E Ratio
- OMAB $19.09
- NUVL N/A
- Revenue Growth
- OMAB N/A
- NUVL N/A
- 52 Week Low
- OMAB $59.08
- NUVL $55.54
- 52 Week High
- OMAB $108.23
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- OMAB 51.56
- NUVL 48.73
- Support Level
- OMAB $100.03
- NUVL $76.42
- Resistance Level
- OMAB $108.23
- NUVL $78.94
- Average True Range (ATR)
- OMAB 2.45
- NUVL 2.71
- MACD
- OMAB -0.77
- NUVL -0.34
- Stochastic Oscillator
- OMAB 23.23
- NUVL 31.73
About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.